Senhwa Biosciences, Inc.

About

Senhwa Biosciences, Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer.

Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan.

Senhwa's CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwa's CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair protein XRCC1 and subsequently enhance the activity of DNA damaging chemotherapy agents.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.

Keywords

targeted cancer therapy, first in class, dna damage response, synthetic lethality, orphan drug, multiple indications, rescue medication, su2ccbcf dream team drug, precision medicine

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No reviews yet. Be the first to review!

Social Links

No social media links available

Photo Gallery

No photos available

Contact Information

Business Info

Location

Business Hours

Business hours not available